Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 1/20 | 0.43 |
| ▸ | METAP2 | P50579 | 8/20 | 0.42 |
| ▸ | METAP1 | P53582 | 6/20 | 0.42 |
| ▸ | MGAM | O43451 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SI | P14410 | 1/20 | 0.41 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18560188 | 0.84 | METAP2 (0.44) | METAP2METAP1MGAMGAASI | |
| SCHEMBL2581812 | 0.82 | TGFBR1 (0.44) | TGFBR1MGAMGAASIMGAM2 | |
| SCHEMBL5497463 | 0.82 | CA14 (0.43) | TGFBR1 | |
| SCHEMBL5451737 | 0.82 | CA14 (0.43) | TGFBR1 | |
| SCHEMBL27490039 | 0.80 | SMN1; SMN2 (0.47) | METAP2METAP1 | |
| SCHEMBL6016762 | 0.80 | METAP2 (0.44) | METAP2METAP1MGAMGAASI | |
| SCHEMBL27491441 | 0.80 | METAP2 (0.44) | METAP2METAP1MGAMGAASI | |
| SCHEMBL6016763 | 0.80 | SMN1; SMN2 (0.47) | METAP2METAP1 | |
| SCHEMBL5814208 | 0.79 | METAP2 (0.46) | METAP2METAP1MGAMGAASI | |
| SCHEMBL5814210 | 0.79 | METAP2 (0.46) | METAP2METAP1MGAMGAASI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070160655-A1 | Hydroxyamate-containing materials for the inhibition of matrix metalloproteinases | SEFTON MICHAEL V | 2007-07-12 | — | — | US | claimed |
| EP-1781714-A1 | HYDROXYAMATE-CONTAINING MATERIALS FOR THE INHIBITION OF MATRIX METALLOPROTEINASES | Rimon Therapeutics Ltd. (CA) | 2007-05-09 | — | — | EP | claimed |
| US-7193007-B2 | Polyethylene glycol/poly(N-iso-propylacrylamide) block copolymers; time-release agents; in-situ implants | CHENG YU-LING | 2007-03-20 | — | — | US | claimed |
| US-7160931-B2 | Thermally reversible implant and filler | CHENG YU-LING | 2007-01-09 | — | — | US | claimed |
| WO-2006002506-A1 | HYDROXYAMATE-CONTAINING MATERIALS FOR THE INHIBITION OF MATRIX METALLOPROTEINASES | RIMON THERAPEUTICS LTD. (CA) | 2006-01-12 | — | — | WO | claimed |
| US-20050020719-A1 | Environment responsive gelling copolymer | CHENG YU-LING (CA) | 2005-01-27 | — | — | US | claimed |
| US-20040213758-A1 | Hydroxyamate-containing materials for the inhibition of matrix metalloproteinases | RIMON THERAPEUTICS LTD. | 2004-10-28 | — | — | US | claimed |
| EP-1272562-A1 | ENVIRONMENT RESPONSIVE GELLING COPOLYMER | CHENG, Yu-Ling (CA) | 2003-01-08 | — | — | EP | claimed |
| WO-2001068768-A1 | ENVIRONMENT RESPONSIVE GELLING COPOLYMER | CHENG YU LING (CA) | 2001-09-20 | — | — | WO | claimed |
| US-20130280331-A1 | Depot Compositions with multiple drug release rate controls and uses thereof | DURECT CORPORATION (US) | 2013-10-24 | — | — | US | disclosed |
| US-20070196415-A1 | DEPOT COMPOSITIONS WITH MULTIPLE DRUG RELEASE RATE CONTROLS AND USES THEREOF | DURECT CORPORATION | 2007-08-23 | — | — | US | disclosed |
| US-20070160655-A1 | Hydroxyamate-containing materials for the inhibition of matrix metalloproteinases | SEFTON MICHAEL V | 2007-07-12 | — | — | US | disclosed |
| US-20070110784-A1 | Thermally reversible implant | RIMON THERAPEUTICS LTD. (CA) | 2007-05-17 | — | — | US | disclosed |
| EP-1781714-A1 | HYDROXYAMATE-CONTAINING MATERIALS FOR THE INHIBITION OF MATRIX METALLOPROTEINASES | Rimon Therapeutics Ltd. (CA) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006002506-A1 | HYDROXYAMATE-CONTAINING MATERIALS FOR THE INHIBITION OF MATRIX METALLOPROTEINASES | RIMON THERAPEUTICS LTD. (CA) | 2006-01-12 | — | — | WO | disclosed |
| US-20050020719-A1 | Environment responsive gelling copolymer | CHENG YU-LING (CA) | 2005-01-27 | — | — | US | disclosed |
| US-20040213758-A1 | Hydroxyamate-containing materials for the inhibition of matrix metalloproteinases | RIMON THERAPEUTICS LTD. | 2004-10-28 | — | — | US | disclosed |
| US-20040029994-A1 | Thermally reversible implant and filler | CHENG YU-LING (CA) | 2004-02-12 | — | — | US | disclosed |
| EP-1272562-A1 | ENVIRONMENT RESPONSIVE GELLING COPOLYMER | CHENG, Yu-Ling (CA) | 2003-01-08 | — | — | EP | disclosed |
| WO-2001068768-A1 | ENVIRONMENT RESPONSIVE GELLING COPOLYMER | CHENG YU LING (CA) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070160655-A1 | Hydroxyamate-containing materials for the inhibition of matrix metalloproteinases | MMP1, MMP14, MMP2 | TGFBR1 833/4885METAP2 135/4885METAP1 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.